WO2009012039A3 - Polymorphes cristallins - Google Patents

Polymorphes cristallins Download PDF

Info

Publication number
WO2009012039A3
WO2009012039A3 PCT/US2008/068558 US2008068558W WO2009012039A3 WO 2009012039 A3 WO2009012039 A3 WO 2009012039A3 US 2008068558 W US2008068558 W US 2008068558W WO 2009012039 A3 WO2009012039 A3 WO 2009012039A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline polymorphs
present
compositions
provides
ethoxycarbonylprop
Prior art date
Application number
PCT/US2008/068558
Other languages
English (en)
Other versions
WO2009012039A2 (fr
Inventor
Joseph J Kopcho
Scott J Hecker
Patricia Frech
Mike Deason
Qun Dang
Karen Gushurst
Donglai Yang
Original Assignee
Metabasis Therapeutics Inc
Joseph J Kopcho
Scott J Hecker
Patricia Frech
Mike Deason
Qun Dang
Karen Gushurst
Donglai Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Joseph J Kopcho, Scott J Hecker, Patricia Frech, Mike Deason, Qun Dang, Karen Gushurst, Donglai Yang filed Critical Metabasis Therapeutics Inc
Publication of WO2009012039A2 publication Critical patent/WO2009012039A2/fr
Publication of WO2009012039A3 publication Critical patent/WO2009012039A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes cristallines de 2-amino-5-(2,2~ diméthylpropionyl)-4-{[5-(N,N'-(2-éthoxycarbonylprop-2-yl)phosphonamido] furan-2-yl}thiazole et des compositions en contenant y compris des compositions pharmaceutiques. La présente invention concerne également des procédés d'utilisation et des procédés de fabrication de telles formes cristallines.
PCT/US2008/068558 2007-07-13 2008-06-27 Polymorphes cristallins WO2009012039A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94968107P 2007-07-13 2007-07-13
US60/949,681 2007-07-13

Publications (2)

Publication Number Publication Date
WO2009012039A2 WO2009012039A2 (fr) 2009-01-22
WO2009012039A3 true WO2009012039A3 (fr) 2009-03-19

Family

ID=40260294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068558 WO2009012039A2 (fr) 2007-07-13 2008-06-27 Polymorphes cristallins

Country Status (1)

Country Link
WO (1) WO2009012039A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2006023515A2 (fr) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs thiazole de la fructose 1,6-bisphosphatase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2006023515A2 (fr) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs thiazole de la fructose 1,6-bisphosphatase

Also Published As

Publication number Publication date
WO2009012039A2 (fr) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2009012039A3 (fr) Polymorphes cristallins
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2006034093A3 (fr) Inhibiteurs de bace
WO2007140385A3 (fr) Nouveaux composés en tant que ligands des récepteurs des cannabinoïdes et utilisations de ceux-ci
WO2008070507A3 (fr) Substances mimétiques de glucocorticoïde, procédés de préparation de celles-ci, compositions pharmaceutiques et utilisations de celles-ci
WO2008051942A3 (fr) Agonistes du récepteur farnésoïde x
WO2006131491A8 (fr) Polymorphes d'ethylester d'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino- methyl)-phenylamino]-methyl}-1-methyl-1h -benzimidazolo-5-carbonyl)-pyridino-2-yl-amino]-propionique
WO2007020213A3 (fr) Derives de thiazolylpiperidines
WO2009016462A3 (fr) Bicyclolactames substitués
WO2007089768A3 (fr) 4-aryl-2-amino-pyrimidines ou 4-aryl-2-aminoalkyl-pyrimidines utilisées comme modulateurs de la jak-2 et leurs procédés d'utilisation
HK1197821A1 (zh) 作為用於製備吡啶- 基-氨基- -噻二唑葡糖激酶激活劑之中間體的吡啶- -基-硫脲和吡啶- -基-胺衍生物
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
WO2007136592A3 (fr) Compositions à base de quinolones substituées et leurs utilisations
WO2007076260A3 (fr) Agonistes de recepteur de farnesoide x
WO2007053765A3 (fr) Cycloalkylpyrrolones substitues utilises en tant que modulateurs allosteriques de glucokinase
WO2009079008A8 (fr) Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
IL195514A (en) Converted Pyridyl Compounds
WO2008052379A3 (fr) Composés organiques
WO2006134499A3 (fr) Derives de 2-(1h-indolylsulfanyl)-aryl amine
WO2008135819A8 (fr) Sel hydrochlorure de 5-r3-f3-tivdroxyphénoxy)azétidin-1-yl]-5-méthyl-2,2- diphénylhexanamide
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2008088779A3 (fr) Formes solides de 5-azacytidine et procédés de préparation de ces dernières
WO2009040314A3 (fr) Nouveaux dérivés de l'acétone substitués par un hétéroaryle, appropriés comme inhibiteurs de la phospholipase a2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781092

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781092

Country of ref document: EP

Kind code of ref document: A2